<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03370666</url>
  </required_header>
  <id_info>
    <org_study_id>07/17</org_study_id>
    <nct_id>NCT03370666</nct_id>
  </id_info>
  <brief_title>High Flow Nasal Therapy Versus Noninvasive Ventilation in COPD Exacerbation</brief_title>
  <official_title>High Flow Nasal Therapy Versus Noninvasive Ventilation in Mild to Moderate Acute Hypercapnic Respiratory Failure: A Non-inferiority Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Ospedaliera Universitaria Mater Domini di Catanzaro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized multicenter non-inferiority trial comparing High flow nasal therapy (HFNT) versus
      Noninvasive ventilation (NIV) in patients with chronic obstructive pulmonary disease (COPD)
      and acute hypercapnic respiratory failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The interventions will be delivered in Emergency Departments or Intensive Care Units.

      The intervention under investigation will be High flow nasal therapy. Investigators will
      deliver HFNT to enrolled patients using any available device able to produce it. The flow
      will be initially set at 60 liters per minute and temperature at 37° C. The target will be an
      oxygen saturation (SpO2) of 88-92%. In case of patient not tolerating these settings, flow
      and temperature will be titrated to the maximum tolerated level. The intervention will last
      until one of the following conditions: 1) physician in charge decide to interrupt HFNT and
      start NIV because the patient shows signs of persisting worsening respiratory failure; 2)
      physician in charge decide to interrupt HFNT and perform endotracheal intubation and invasive
      mechanical ventilation because patient shows one or more of these conditions: respiratory
      arrest, respiratory pauses with loss of consciousness, psychomotor agitation making nursing
      care impossible, heart rate &lt; 50 with loss of alertness, hemodynamic instability with
      systolic arterial blood pressure &lt;70 mmHg, development of conditions requiring intubation
      either to protect the airway or to manage copious tracheal secretions, inability to tolerate
      the devices; 3) clinical improvement defined as all these conditions: normal mental status,
      hemodynamic stability, respiratory rate below 25 per minute, absence of activation of
      accessory respiratory muscles and paradoxical abdominal motion, no dyspnea arterial pH &gt;
      7.35, Arterial partial pressure of carbon dioxide (PaCO2) &lt; 70 mmHg and Arterial partial
      pressure of oxygen (PaO2) &gt; 55 mmHg with an inspired oxygen fraction (FiO2) &lt; 0.35.

      In case of temporary interruption of the intervention for any cause, patients should receive
      oxygen supplementation with Venturi mask with a target of SpO2 88-92%.The comparator will be
      non invasive ventilation (NIV). NIV must be delivered by full or oronasal mask. The
      ventilator settings will be decided according to the usual practice: maximal tolerated
      inspiratory pressure to obtain a measured or estimated expired tidal volume of 6-8 mL·kg-1 of
      body weight and a positive end expiratory pressure (PEEP) between 3 and 5 cmH2O. An interface
      rotational strategy will be allowed among only different types of masks.

      The intervention will last until one of the following conditions: 1) physician in charge
      decide to interrupt NIV and perform endotracheal intubation and invasive mechanical
      ventilation because patient shows one or more of these conditions: respiratory arrest,
      respiratory pauses with loss of consciousness, psychomotor agitation making nursing care
      impossible, heart rate &lt; 50 with loss of alertness, hemodynamic instability with systolic
      arterial blood pressure &lt;70 mmHg, development of conditions requiring intubation either to
      protect the airway or to manage copious tracheal secretions, inability to tolerate the
      devices; 2) clinical improvement defined as all these conditions: normal mental status,
      hemodynamic stability, respiratory rate below 25 per minute, absence of activation of
      accessory respiratory muscles and paradoxical abdominal motion, no dyspnoea arterial pH &gt;
      7.35, Arterial partial pressure of carbon dioxide (PaCO2) &lt; 70 mmHg and Arterial partial
      pressure of oxygen (PaO2) &gt; 55 mmHg with an inspired oxygen fraction (FiO2) &lt; 0.35.

      In case of temporary interruption of NIV for any cause, patients should receive oxygen
      supplementation with Venturi mask with a target of SpO2 88-92%.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2018</start_date>
  <completion_date type="Anticipated">February 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Non-inferiority</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arterial partial pressure of carbon dioxide (PaCO2)</measure>
    <time_frame>2 hours after randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dyspnea evaluated with Borg dyspnea scale</measure>
    <time_frame>2 and 6 hours after randomization</time_frame>
    <description>Borg dyspnea scale: this is a 12-point validated scale that rates patient's difficulty in breathing. It starts at number 0 where breathing causes no difficulty at all and progresses through number 10 where breathing difficulty is maximal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial partial pressure of carbon dioxide (PaCO2)</measure>
    <time_frame>6 hours after randomization</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Respiratory rate</measure>
    <time_frame>2 and 6 hours after randomization</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Discontinuation of the interventions</measure>
    <time_frame>At 6 hours after randomization</time_frame>
    <description>The inability of the patient to continue the treatment while there was still an indication for ventilatory support</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall discomfort related to the interface</measure>
    <time_frame>At 6 hours after randomization</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Presence of side effects</measure>
    <time_frame>At 6 hours after randomization</time_frame>
    <description>I.e., complaining for noise or too high temperature of flow, claustrophobia, gastric distension, vomiting, sweating, tightness</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of treatment failure</measure>
    <time_frame>At 6 hours after randomization</time_frame>
    <description>defined as the presence of one or more of the following: arterial partial pressure of carbon dioxide (PaCO2) reduction, no change or reduction &lt; 10 mmHg from baseline, worsening or no improvement in dyspnoea, respiratory rate &gt; 30 breaths per minute, use of accessory respiratory muscles or paradoxical abdominal movement</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of endotracheal intubation</measure>
    <time_frame>At 6 hours after randomization</time_frame>
    <description>Number of patients requiring endotracheal intubation</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>COPD Exacerbation</condition>
  <arm_group>
    <arm_group_label>HFNT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HFNT performed with any available device. The flow will be initially set at 60 liters per minute and temperature at 37° C. The target will be an oxygen saturation (SpO2) of 88-92%. In case of patient not tolerating these settings, flow and temperature will be titrated to the maximum tolerated level.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NIV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NIV must be delivered by full or oronasal mask with any available ventilator. The ventilator settings will be decided according to the usual practice: maximal tolerated inspiratory pressure to obtain a measured or estimated expired tidal volume of 6-8 mL·kg-1 of body weight and a positive end expiratory pressure (PEEP) between 3 and 5 cmH2O. An interface rotational strategy will be allowed among only different types of masks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HFNT</intervention_name>
    <description>High flow nasal therapy</description>
    <arm_group_label>HFNT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NIV</intervention_name>
    <description>Noninvasive ventilation</description>
    <arm_group_label>NIV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of chronic obstructive pulmonary disease (COPD) and acute hypercapnic
             respiratory failure;

          -  7.25 &lt; pH &lt; 7.35;

          -  Arterial Partial pressure of carbon dioxide (PaCO2) equal or greater than 55 mmHg;

          -  Age &gt; 18 years/old

        Exclusion Criteria:

          -  Invasive mechanical ventilation in the last 60 days

          -  Use of any form of noninvasive ventilation or high flow oxygen through nasal cannula
             (HFNT) prior to study enrollment after the onset of acute hypercapnic respiratory
             failure (AHRF);

          -  Noninvasive home care ventilation;

          -  Unstable clinical condition (need for vasopressors for &gt;24 h, acute coronary syndrome
             or life-threatening arrhythmias);

          -  Refusal of treatment;

          -  Agitation (RASS &gt;= +2) or non-cooperation (Kelly Matthay &gt;=5);

          -  Failure of more than two organs;

          -  Cardiac arrest;

          -  Respiratory arrest requiring tracheal intubation;

          -  Recent trauma or burns of the neck and face;

          -  Pregnancy;

          -  Refusal of consent;

          -  Inclusion in other research protocols.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paolo Navalesi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Azienda Ospedaliera Universitaria Mater Domini di Catanzaro</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Cortegiani, MD</last_name>
    <phone>+390916552730</phone>
    <email>cortegiania@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Federico Longhini, MD</last_name>
    <phone>+390916552730</phone>
    <email>federico.longhini@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedale S. Donato</name>
      <address>
        <city>Arezzo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raffaele Scala</last_name>
    </contact>
    <investigator>
      <last_name>Raffaele Scala</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST - Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberto Cosentini</last_name>
    </contact>
    <investigator>
      <last_name>Roberto Cosentini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Sant'Orsola Malpighi. Università Alma Mater</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefano Nava</last_name>
    </contact>
    <investigator>
      <last_name>Stefano Nava</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Mater Domini</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paolo Navalesi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eugenio Garofalo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Bruni</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone. Università degli Studi di Palermo</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Cortegiani</last_name>
    </contact>
    <investigator>
      <last_name>Cesare Gregoretti</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Maugeri</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annalisa Carlucci</last_name>
    </contact>
    <investigator>
      <last_name>Annalisa Carlucci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Madonna del Soccorso</name>
      <address>
        <city>San Benedetto Del Tronto</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paolo Groff</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Humanitas Gradenigo</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giorgio Carbone</last_name>
    </contact>
    <investigator>
      <last_name>Giorgio Carbone</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giovanni Bosco</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Franco Aprà</last_name>
    </contact>
    <investigator>
      <last_name>Franco Aprà</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Universitaria Integrata di Udine</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luigi Vetrugno</last_name>
    </contact>
    <investigator>
      <last_name>Luigi Vetrugno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2017</study_first_submitted>
  <study_first_submitted_qc>December 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2017</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo</investigator_affiliation>
    <investigator_full_name>Andrea Cortegiani, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

